Regression of atherosclerosis: insights from animal and clinical studies

Area of Science:

• Cardiovascular Science
• Molecular Biology
• Biochemistry

Background:

• Atherosclerosis regression, once a distant goal, is now attainable based on research since the 1920s.
• Successful regression strategies involve significant improvements in plasma lipoprotein profiles.
• Key interventions include reducing atherogenic apolipoprotein B and boosting reverse cholesterol transport.

Purpose of the Study:

• To review the mechanisms and key molecular players involved in atherosclerosis regression.
• To highlight the roles of Liver X Receptor (LXR), High-Density Lipoprotein (HDL), and CCR7 in mediating plaque regression.

Main Methods:

• Literature review of studies on atherosclerosis regression.
• Analysis of mechanisms contributing to atherosclerotic lesion shrinkage.
• Identification of molecular mediators of regression.

Main Results:

• Mechanisms for lesion shrinkage include reduced retention of apolipoprotein B, lipid efflux from plaques, foam cell emigration, and infiltration of phagocytes.
• Key molecular players like LXR, HDL, and CCR7 are crucial in mediating regression processes.
• Studies demonstrate that improving lipoprotein profiles is central to achieving atherosclerosis regression.

Conclusions:

• Significant advancements have been made in understanding atherosclerosis regression.
• Unanswered questions necessitate further preclinical and clinical investigations.
• Developing novel agents and gaining deeper mechanistic insights are vital for future progress in treating atherosclerosis.